NCT05529849View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

December 12, 2022

Study Completion Date

February 20, 2023

Conditions
Cachexia
Interventions
DRUG

TCMCB07

Subcutaneous injection of TCMCB07

DRUG

Placebo

Matching subcutaneous placebo

Trial Locations (1)

33126

Quotient Sciences -- Miami, Inc., Miami

Sponsors

Lead Sponsor

Endevica Bio
All Listed Sponsors
lead

Endevica Bio

INDUSTRY